The effect of -asarone on impairment of cognitive performance caused by amnesic drug scopolamine was investigated. Treatment with -asarone attenuated scopolamine-induced cognitive deficits as evaluated by passive avoidance and Y-maze test. Administration of -asarone for 15 d improved memory and cognitive function as indicated by an increase in transfer latency time and spontaneous alternation in passive avoidance and the Y-maze test respectively. To understand the action of -asarone, the levels of acetylcholinesterase (AChE), malondialdehyde (MDA), and superoxide dismutase (SOD) in the hippocampus (Hippo) and cerebral cortex (CC) of scopolamine-induced amnesic mice were evaluated. The mice treated with Scopolamine showed increased activity of AChE, MDA and SOD levels in both the Hippo and the CC area. Treatment withasarone attenuated the increased activity of AChE and normalized the MDA and SOD levels in the Hippo and the CC area in the scopolamine treated amnesic mice. These results suggest that -asarone has a beneficial effect in cognitive impairment induced by dysfunction of cholinergic system in brain through inhibition of AChE activity and by influencing the antioxidant defense mechanism.
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Alzheimer's disease (AD) is characterized by loss of memory accompanied by degeneration of basal forebrain cortical cholinergic neurons and dysfunction of central cholinergic neurotransmission. Mounting evidence also suggests that oxidative stress plays a major role in the cognitive deficits observed in AD. 1, 2) Scopolamine, a muscarinic receptor antagonist, is reported to impair long-term potentiation (LTP), and is frequently used as a model in screening anti-amnesic drugs. [3] [4] [5] Acetylcholinesterase (AChE) inhibitors ameliorate the negative effects of scopolamine on spatial memory in various behavioral tests. 6, 7) Several reports have also indicated that memory impairment in scopolamine animal model is also associated with increased oxidative stress within the rat brain. 1, 8, 9) Cognition represents different stages including acquisition, consolidation, retention, retrieval and performance. 10) Cognition deficits produced by cholinergic antagonism mimic the cognitive symptomology of AD.
11) Drugs approved for AD therapy act by preventing the degradation of acetylcholine (ACh) by AChE enzyme in the brain. 12) AChE inhibition served as a strategy for the treatment of AD, senile dementia, ataxia and Parkinson's disease. 12) In addition, a number of studies indicate that the brain in AD and other neurodegenerative diseases is under increased oxidative stress and this may have a role in the cognitive impairment found in these disorders. [13] [14] [15] One of the direct evidence supporting increased oxidative stress in AD is the increased levels of oxidative markers such as malondialdehyde (MDA), superoxide dismuatse (SOD), advanced glycation end products, peroxynitrite, and heme oxygenase-1 in neurofibrillary tangles and senile plaques in AD brains. 16 ) AChE inhibitors such as donepezil 17) and antioxidants such as vitamin E 18) are used clinically in AD therapy, because they delay disease progression, but currently there is no curative therapy for AD.
Traditional use in Indian, Korean, and Mexican countries and pharmacological reports suggest that certain plant families, such as Araceae and Annonaceae, are effective in improving patient conditions in cognitive dysfunction. In Ayurveda, an Indian system of medicine, Aindrarasayana and Brahmarasayana are two formulations containing Acorus extracts used to alleviate dementia. 19) An Extract of Acori graminei also used as remedy for cognitive impairment and antiaging effect. 20) Experimental evidence indicates that these plants contain -asarone (Fig. 1A) as one of their major active constituent.
Pharmacologically, -asarone, was reported to possess anticonvulsant, 21) antihyperlipidemic, 22) and antiinflammatory, antioxidant properties.
23) It also exhibits protective properties against brain diseases and increases the levels of antioxidants such as Vitamin C and E in experimental animals. 23) Previous study postulated that neuroprotective activity for -asarone by blocking the N-methyl-D-aspartate receptor (NMDA), a glutamate subtype receptor. 24) But to date, the effect of -asarone on cognitive impairments observed in scopolamine amnesic mice and the underlying mechanisms have not been scientifically documented. Hence, the present study was undertaken to evaluate the cognitive and behavioral 
Material and Methods
Reagents and chemicals. Scopolamine hydrochloride, -asarone, tacrine hydrochloride hydrate (THA), and methylcellulose were purchased from Sigma (St. Louis, MO). Tween 80 was from Calbiochem (Gibbstown, NJ).
Experimental animals. ICR mice 6 weeks of age were obtained from the Central Lab Animal facility (Central Lab, Seoul). Animal were housed in group of four per cage on a light and temperature controlled (23 AE 1 ) schedule under a 12/12 h light and dark cycle. The Animals were provided with food and water ad libitum. They were acclimatized under standard conditions for 2 week before starting the behavioral experiment. All experimental procedures were carried out in accordance with the NIH Guide for care (NIH Publication no. 85-23, 1985, revised 1996) and were approved by the Institutional Animal Care and Use Committee at Konkuk University.
Animal grouping and drug treatment. The mice were divided into six groups (n ¼ 8 per group) vehicle, scopolamine 2 mg/kg, -asarone 3 mg/kg, -asarone 10 mg/kg, -asarone 30 mg/kg and THA 10 mg/ kg. Different doses of -asarone were prepared by dissolving -asarone in 0.5% Methylcellulose solution containing 1% Tween 80 just prior to dosing. Scopolamine was prepared in saline and THA was dissolved in distilled water. All the mice except for the vehicle group received scopolamine hydrochloride (2 mg/kg, i.p.) 5 min prior to acquisition trial of passive avoidance and 30 min before the Y-maze test. -asarone was dosed for 15d before scopolamine injection.
Step-through passive avoidance test. Experimental sessions were conducted using gemini active and passive avoidance system (San Diego Instruments, San Diego, CA) connected to a computer as the procedure described, 25) with slight modification. This has a lighted and a dark compartment with a computer-controlled guillotine door between them. Each animal was familiarized with the behavioral apparatus for 2-3 min the day before the training session. Delivery of electric shocks the raising and lowering of the door were controlled by the computer. On the day of training, the animals were placed in the lighted compartment with the head facing the wall. After an acclimatization period of 30 s, the guillotine door automatically opened and the animal was subjected to a trial of 270 s. Entry into the dark compartment automatically shut the door and the subject was punished with single low intensity foot shock of 0.5 mA for 5 s. The latencies at which the animals stepped into the dark from the bright compartment were recorded by the computer. The transfer from one compartment to another was recorded as transfer latency time (TLT). The 1st trial was for acquisition and retention was tested by a 2nd trial, given 24 h after the 1st trial. No shock was delivered in the 2nd trial. The criterion for learning was taken as an increase in the TLT on 2nd trial (retention) as compared to 1st trial (acquisition).
Spontaneous alternation performance (Y-maze test). Immediate working memory was assessed by recording spontaneous alternation behavior during a single session in a Y-maze. Each arm was 40 cm long, 12 cm wide, and 30 cm high. The procedure was similar described previously. 4) Each mouse, naïve to the maze, was placed at the end of one arm and allowed to move freely through the maze during an 8 min session, and arm entries were counted. The series of arm entries was recorded visually by a person blinded to treatment group, and arm entry was considered to be completed when hind paws of the mouse were completely placed in the arm. Alternation was defined as successive entries into the three arms, on overlapping triplet sets. The effect was calculated as percentage alternation according to the formula: percentage alternation = [(number of alternations)/(total number of arm entries -2)] Â 100.
Tissue acquisition. Following the recall phase of passive avoidance mice were given one further treatment of -asarone/THA and/or scopolamine prior to sacrifice. Time of sacrifice was 30 min following scopolamine injection or 60 min following -asarone/THA administration. The mice were sacrificed by decapitation; after which the brain of each mouse was exposed from the dorsal side by incising the skull. The whole brain was then carefully removed from the mouse, chilled on ice and then the Hippo and CC areas were dissected as described previously 26) for estimating MDA levels (n ¼ 4), AChE activity, and SOD activity (n ¼ 4).
MDA levels. MDA levels were monitored to detect changes in lipid peroxidation following treatment using Western blot (OxiselectÔ MDA Immunoblot Kit, Cell Biolabs, San Diego, CA). To obtain total tissue lysate, 10% w/v of RIPA buffer (1 Â PBS, 1% NP-40, 0.5% sodium deoxycholate, 0.1% SDS, with freshly added protease inhibitor cocktail) was added to the CC and hippocampal tissues. The tissues were homogenized and passed through a 1 mL tuberculin syringe, incubated for 10 min on ice and centrifuged at 14;000 Â rpm for 10 min at 4
C. The protein concentration was determined by DC protein assay Bio-Rad (Hercules, CA), and tissue supernatant containing 20 mg/mL of protein were separated on 10% sodium dodecyl sulfatepolyacrylamide gels (SDS-PAGE). Electrophoresis was performed and the proteins were transferred to PVDF membranes (Millipore, MA) using an electro blotting apparatus (Bio-Rad, CA). The membranes were blocked for 1 h in TBS containing 0.1% Tween-20 and 5% dry Skim milk, and then were incubated overnight with primary antibodies anti-MDA, diluted 1:1,000, followed by incubation for 1 h with horseradish peroxidase-conjugated secondary antibodies (diluted 1:1,000). The optical densities of the antibody-specific bands were analyzed by a Luminescent Image Analyzer, LAS-3000 (Fuji, Tokyo).
Determination of AChE and SOD activity. Brain homogenate was prepared in 10% w/v 0.1 M Phosphate buffer. AChE activity was estimated with the help of Biochain kit (Biochain, CA) as per manufactur's instructions, using the principle of colorimetric assay as previously described.
27) SOD was measured as an additional indicator of change in oxidative mechanisms following treatment. SOD was determined using Dojindo Molecular Technology kit (Dojindo, Maryland) as per manufacturer's instructions.
Statistical analysis. All data were analyzed using Graph Pad Prism, version 5.01. They were expressed as mean AE SEM analyzed by One Way ANOVA followed by Tukey's Multiple Comparison Test. The comparisons of interest in present experiment were the effect of each treatment compared to control and scopolamine-treated versus -asarone and scopolamine treated mice. Values of p < 0:05 were considered statistically significant.
Results and Discussion
In the step-through passive avoidance test TLT significantly increased on the 2nd trial (213:5 AE 26:9) as compared to the 1st trial (14:6 AE 2:3) in the control group, but in the scopolamine group there was no significant increase on the 2nd trial (21: respectively. 10 and 30 mg/kg doses showed significant increase as to the compared with scopolamine group (p < 0:05 and p < 0:01 vs. scopolamine group respectively). There was no significant difference in TLT on 1st trial among the various groups. THA, which was used as positive control in the study increased TLT on the 2nd trial (156:23 AE 38:35) as compared with 1st trial (32:5 AE 10:9) (p < 0:05) (Fig. 1B) .
In spontaneous alternation assessed using Y-maze test, scopolamine (2 mg/kg, i.p) significantly (p < 0:001) decreased the percentage alternation when tested 30 min after the administration to mice. Pre-treatment with -asarone at the indicated dosages (3, 10, and 30 mg/kg, p.o.) ameliorated the scopolamine-induced decreased percentage alternation in mice. Results indicate that 10 and 30 mg/kg exhibited almost similar efficacy (p < 0:001) as compared with 3 mg/kg dose (p < 0:01). Furthermore, no significant difference was observed in total arm entries for any group ( Fig. 2A  and B) . Figure 3 shows the effect of AChE evaluated in CC and Hippo after treatment. Scopolamine treatment caused a 16% increase in AChE in CC and a 32% increase in Hippo (p < 0:01) from the vehicle group, whereas prophylactic treatment with -asarone decreased AChE activity 17% (p < 0:01), 37% (p < 0:001) and 31% (p < 0:001) at 3, 10, and 30 mg/kg respectively in CC. In Hippo, different doses of -asarone (3, 10, and 30 mg/kg) showed 20% (p < 0:001), 33% (p < 0:001) and 34% (p < 0:001) decreased activity of AChE respectively. THA showed 33% (p < 0:001) and 4% (p < 0:01) inhibition of AChE in CC and Hippo respectively (Fig. 3A and B) .
Increased MDA levels have been found to be important marker of in vivo lipid peroxidation. Treatment with scopolamine caused increased MDA levels (p < 0:001) in both CC and Hippo. Prophylactic treatment with -asarone inhibited scopolamine-induced increased expression of MDA in both areas of the brain. In CC 10 mg/kg of -asarone was found to be more effective in lowering MDA levels than 3 or 30 mg/kg, albeit all doses were significant (p < 0:001). Moreover, -asarone showed dose-dependent inhibition of MDA in Hippo (p < 0:05 at 3 mg/kg, and p < 0:001 at 10 and 30 mg/kg). THA mitigated MDA in both CC and Hippo (p < 0:001) (Fig. 4A and B) .
SOD activity was determined and expressed as % of control group. Scopolamine treatment significantly increased SOD activity in the CC (p < 0:001) and Hippo (p < 0:05) regions of the brain. A 30 mg/kg dose of -asarone significantly (p < 0:05) reduced SOD activity in both CC and Hippo. THA significantly mitigated SOD levels in Hippo (Fig. 4C) .
It is well documented that the central cholinergic neurons are important in the acquisition and postacquisition (consolidation) performance of a variety of learned behaviors. There is substantial clinical evidence that muscarinic receptor blockade by drugs like scopolamine results in disruption of behavioral, working (shortterm) memory, retrieval from reference (long-term) memory, attention, decisional processes, movement, strategy selection and altered sensory processing. 28) Cholinergic enhancers particularly AChE inhibitors such as physostigmine, tacrine, and velnacrine, facilitate cognitive processes in animals and humans, 6, 7, 29) and these agents are the mainstay of anti-dementia drug therapy. 30) Many clinical studies have also reported that oxidative stress and free radicals are implicated in the process of cognitive impairment. 1, 2) Therefore, developing agents that regulate cholinergic system and improve oxidative defense status might be useful in ameliorating cognitive dysfunction.
In the present study, cognitive impairment was achieved by scopolamine injection, which acts both by disrupting cholinergic activity and increasing oxidative stress within the brains of mice. 1) In a passive avoidance test, the animals upon exposure to the first trial acquire the information that entry into dark chamber results in painful experience of electric shock, and the cognitive ability of the animals was reflected by avoidance of the entry (a judgment based on successful retention and recall of the acquired information). Scopolamine administration before the acquisition trial impaired the learning process (amnesia). When animals were checked in retention trial there was no increase in TLT which reflects cognitive impairment. -Asarone caused increase in TLT in a retention trial of passive avoidance at doses of 10 and 30 mg/kg, while at a lower dose (3 mg/ kg), it did not show any significant effect. The positive control THA, an AChE inhibitor and anti-dementic drug, also significantly reversed scopolamine-induced amnesia.
In the Y-maze test, the spontaneous alteration behavior of mice, which is considered to be an indicator of short-term memory, was evaluated. Scopolamine at a dose of 2 mg/kg decreased alternation behavior with no significant change in total arm entry, in accordance with previous study. 31) There was no significant difference in total arm entry in any of the groups tested. One reason for this may be that -asarone and scopolamine did not have any significant influence on locomotion or anxiety. However, -asarone pre-treatment attenuated scopolamine induced alternation behavior in a dose-dependent manner. THA at dose of 10 mg/kg also significantly attenuated the scopolamine effect in Y-maze test.
Severity of dementia is correlated with cholinergic hypofunction. Some have postulated that the cholinergic system plays important roles in learning and memory. 32) The most important changes observed in AD patients are a decrease in hippocampal and cortical levels of the neurotransmitter ACh. 12) Hence, AChE levels were analyzed in the Hippo and CC. It appeared that scopolamine treatment influenced AChE activity to a significant extent indicating a deficit of ACh. It is noteworthy that administration of -asarone at doses of 3, 10, and 30 mg/kg for 15 d inhibited AChE activity in both Hippo and CC. THA at the dose of 10 mg was effective in countering the scopolamine-induced changes in the Hippo and CC.
This study also evaluated whether cognition impaired by scopolamine is associated with altered oxidative stress indices. Scopolamine-treated mice showed elevated MDA and SOD levels. Reports have also postulated that scopolamine additionally triggers reactive oxygen species, including free-radical injury. Memory impairment in the scopolamine amnesic rats showed a similar pattern of oxidative damage to that of patients with mild cognitive impairment. Our results are in agreement with previous reports that memory impairment induced by the administration of scopolamine is associated with increased peroxidation and overproduction of free radicals, which reduces the levels of endogenous antioxidants. [33] [34] [35] The Hippocampus is the main area involved in learning and memory. Cognitive deficits are observed in clinical situation like AD or experimental animal model involving lesion to the hippocampus.
28) The probable mechanism of antioxidant action on cognition is protection of hippocampal synaptic plasticity and long-term potential. In our study, -asarone decreased MDA levels significantly and dosedependently in Hippo. All doses showed significant effects although 10 mg/kg was most effective in the CC of mouse brain. A dose-dependent decrease was observed in the SOD level in the CC and Hippo and highest dose, 30 mg/kg, significantly restored SOD level in CC and Hippo of mouse brain tissues. The data obtained in the present study are in agreement with earlier reports that a wide range of antioxidants improve the cognitive ability against scopolamine through their inhibitory actions on both AChE and free radicals. [36] [37] [38] In conclusion, -asarone effectively ameliorated the behavioral deficits incurred by scopolamine in mice. The effects of -asarone were found to be mediated by inhibition of AChE activity and by influences antioxidant activity. Further studies are required to establish the efficacy and safety dosage regimens of -asarone. This study indicates the significant therapeutic value of -asarone in alleviating cognitive impairment observed in several neurodegenerative diseases including AD.
